U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H17NO2
Molecular Weight 243.301
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AGOMELATINE

SMILES

COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1

InChI

InChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula C15H17NO2
Molecular Weight 243.301
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. Agomelatine is indicated for the treatment of major depressive episodes.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.1 nM [Ki]
0.12 nM [Ki]
6.2 null [pKi]
6.6 null [pKi]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VALDOXAN

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose is 25 mg once daily taken orally at bedtime. After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime. Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of LFT monitoring.
Route of Administration: Oral
In Vitro Use Guide
hypothalamic suprachiasmatic nucleus firing rates were dose-dependently suppressed by 19.2-80.9% following perfusion of 0.04-0.32mM agomelatine (p<0.001, IC50=0.14mM).
Substance Class Chemical
Record UNII
137R1N49AD
Record Status Validated (UNII)
Record Version